What is the purpose of randomization concealment?

Enhance your knowledge of clinical trials with the ACRP GCP and Clinical Trial Principles Test. Study using diverse question types, hints, and immediate explanations. Equip yourself with essential tools for success!

Multiple Choice

What is the purpose of randomization concealment?

Explanation:
Allocation concealment is about hiding the upcoming treatment assignment from the person enrolling participants, so the assignment remains unknown until the moment the participant is actually assigned. This prevents selection bias, because if the allocator can predict or influence which treatment comes next, they might steer enrolling patients with certain characteristics into one group, skewing the study’s balance. By using mechanisms like centralized randomization, sealed opaque envelopes, or secure online systems that reveal the assignment only after enrollment, the randomization process stays unbiased and the groups stay comparable at baseline. This concept is different from blinding, which aims to prevent bias after assignment by keeping participants or assessors unaware of the treatment. The goal isn’t to speed enrollment or to let researchers choose the treatment, and it isn’t about revealing allocation before or during enrollment—it's about keeping the allocation unknown until the point of assignment to safeguard trial integrity.

Allocation concealment is about hiding the upcoming treatment assignment from the person enrolling participants, so the assignment remains unknown until the moment the participant is actually assigned. This prevents selection bias, because if the allocator can predict or influence which treatment comes next, they might steer enrolling patients with certain characteristics into one group, skewing the study’s balance. By using mechanisms like centralized randomization, sealed opaque envelopes, or secure online systems that reveal the assignment only after enrollment, the randomization process stays unbiased and the groups stay comparable at baseline. This concept is different from blinding, which aims to prevent bias after assignment by keeping participants or assessors unaware of the treatment. The goal isn’t to speed enrollment or to let researchers choose the treatment, and it isn’t about revealing allocation before or during enrollment—it's about keeping the allocation unknown until the point of assignment to safeguard trial integrity.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy